On November 7, 2019 Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, reported that it will present at the Society for the Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 34th Annual Meeting in National Harbor, MD (Press release, Surface Oncology, NOV 7, 2019, View Source [SID1234550596]). The presentations will include posters highlighting preclinical data from three programs in the Company’s portfolio, SRF388 (targeting IL-27), SRF617 (targeting CD39) and SRF231 (targeting CD47).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Each therapeutic candidate at Surface provides a compelling and differentiated biological rationale as an anti-tumor agent, with SRF617 and SRF388 IND filings anticipated in the fourth quarter of 2019," said Vito Palombella, Ph.D., chief scientific officer of Surface Oncology. "As demonstrated in these preclinical data presentations, the Surface team performs world-class research that has given us unique insights into these important immunomodulatory pathways."
Selected details of preclinical data presented in the posters include:
Friday, November 8, 2019:
Poster #P805: SRF388, a first-in-class, fully human monoclonal antibody targeting IL-27, blocks the immunoregulatory effects of IL-27 in immune cells and demonstrates preclinical in vivo anti-tumor activity
SRF388 binds to the p28 subunit of IL-27 with high affinity, inhibits IL-27 from interacting with IL-27RA, and inhibits IL-27-induced STAT1 phosphorylation in cells.
By preventing IL-27 from interacting with IL-27RA, SRF388 inhibits IL-27-stimulated immunoregulatory receptor expression.
SRF388 blocks IL-27 inhibition of PD-1-mediated cytokine production.
SRF388 inhibits the growth of disseminated lung tumors in vivo.
Saturday, November 9, 2019:
Poster #P652: The fully human antibody SRF617 is a potent enzymatic inhibitor of CD39 with strong immunomodulatory activity
SRF617 inhibits the enzymatic activity of CD39 on cells.
By blocking CD39, SRF617 enhances total CD4 cell proliferation and dendritic cell maturation in the presence of exogenous ATP.
SRF617 inhibits CD39 enzymatic activity in tumors, reduces systemic adenosine levels, inhibits tumor growth and increases tumor associated macrophages in preclinical tumor models.
Combination of a murine surrogate of SRF617 with anti-PD-1 inhibition significantly increases survival versus anti-PD-1 inhibition alone, in a preclinical mouse tumor model.
Poster# P272: SRF231, a fully human high-affinity anti-CD47 antibody, exerts potent preclinical antitumor activity through engagement of the Fc receptor (FcR), CD32a
SRF231 delivers an activating signal to myeloid cells via interactions between the Fc region of SRF231 and CD32a expressed on myeloid cells.
SRF231 displays favorable preclinical characteristics with respect to receptor occupancy/tumor exposure/efficacy relationship.
The posters will be available to view on the Surface Oncology website, here.
Individuals wishing to attend the Surface R&D day on November 18th should contact [email protected].